Twitter | Search | |
Bolanos Natacha
Lymphoma Coalition's Regional Manager Europe. EHA EAC and ESMO PAWG Member, Patient Advocate interested in R&D, Capacity Building, Health Policy...
732
Tweets
268
Following
340
Followers
Tweets
Bolanos Natacha 1h
Are you interested in how can speed up research and treatment development? Let me know! The T-Cell consortium will meet at . Find me at
Reply Retweet Like
Bolanos Natacha 2h
Lymphoma Coalition works to improve accross the journey. Come and visit us! At There is lot we can do together!
Reply Retweet Like
Bolanos Natacha retweeted
Michael Hallek Jun 9
Following the publication of the CLL14 trial (Fischer et al., 2019 Jun 6;380(23):2225-2236), we have updated the 1L treatment algorithm for patients. I thank many colleagues, including members of HOVON, Nordic CLL group & for invaluable input.
Reply Retweet Like
Bolanos Natacha retweeted
Erin LeDell Jun 14
Happy to share our Workshop paper, "An Open Source AutoML Benchmark". We present a new AutoML benchmarking system and include results on: H2O AutoML, auto-sklearn, TPOT, Auto-WEKA 📰 Paper: 👩‍💻 Code:
Reply Retweet Like
Bolanos Natacha retweeted
Judith Trotman 15h
Roll-up, roll-up Ladies and Gentlemen. shares his passion for treating and studying cell lymphoma with novel therapy combinations at
Reply Retweet Like
Bolanos Natacha 14h
Thanks to , medical advisor for conducting and leading the discussion at with Dr U. Jager
Reply Retweet Like
Bolanos Natacha 14h
CLL first line treatment updated. JUNE 2019 by at
Reply Retweet Like
Bolanos Natacha 15h
Summary of presentation on on pros and cons chemotherapy-free regimens for Mantle Cell at
Reply Retweet Like
Bolanos Natacha 15h
I'm proud to be with at getting important lessons to report back to membership
Reply Retweet Like
Bolanos Natacha 15h
Summary of Dr N. Fowler beautiful presentation at
Reply Retweet Like
Bolanos Natacha 15h
How to predict response depends on subgroups definition promotes the correst diagnosis of different Lymphoma subentities
Reply Retweet Like
Bolanos Natacha 16h
SMART START trial by Dr U. Jager at
Reply Retweet Like
Bolanos Natacha 16h
Learnings R-CHOP / R-CHOP +X in first line DLBCL
Reply Retweet Like
Bolanos Natacha 16h
Keeping in mind important considerations on DLBCL
Reply Retweet Like
Bolanos Natacha 16h
About to start such a big session on new chemotherapy oy free approaches for Lymphomas. Great speakers!. Meaningful topics partner with to inform patients and increase capacity of patient advocates.
Reply Retweet Like
Bolanos Natacha 17h
will be reporting back to members worldwide. Follow us!
Reply Retweet Like
Bolanos Natacha 17h
is also in Lugano! Relevant for bringing capacity to our members worldwide!
Reply Retweet Like
Bolanos Natacha 17h
Neurotoxicity grading systems. Again, urgent need to work with only one system. We nned comparable . Currently trials are not comparable so best value therapy is not clear. This is not acceptable anymore.
Reply Retweet Like
Bolanos Natacha 17h
Important differences among the Penn and Lee grading scale in therapy. encourage investigators and scientific societies to agree on a consensus. For registry purposes we need comparable data!
Reply Retweet Like
Bolanos Natacha 17h
advocates for the use of consensus grading scale to assess therapy adverse effects. Particularly CRS and neurotoxicity. We nned comparable data.
Reply Retweet Like